LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

LLY

1,081.58

-1.94%↓

JNJ

224

-0.52%↓

ABBV

213.26

-2.16%↓

UNH

378.3

-0.09%↓

MRK

115.22

-2.85%↓

Home・Lista de Ações・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Abrir

SetorSaúde

66.77 0.45

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

65.62

Máximo

67.86

Indicadores-chave
By Trading Economics
Rendimento	292M 150M
Vendas	-75M 377M
P/E Médio do Setor	24.112 50.102
EPS	1.221
Margem de lucro	39.832
Funcionários	423
EBITDA	-63M 218M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+28.94% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	501M 8.2B
Abertura anterior	66.32
Fecho anterior	66.77

Sentimento de Notícias

By Acuity

50%

124 / 344 Ranking em Healthcare

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 de mai. de 2026, 22:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 de mai. de 2026, 23:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 de mai. de 2026, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 de mai. de 2026, 20:53 UTC

Ganhos

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 20:33 UTC

Conversa de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 de mai. de 2026, 20:11 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 19:47 UTC

Ganhos

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 de mai. de 2026, 19:36 UTC

Conversa de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 de mai. de 2026, 19:34 UTC

Conversa de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 de mai. de 2026, 19:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 de mai. de 2026, 18:19 UTC

Conversa de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 de mai. de 2026, 18:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 de mai. de 2026, 18:11 UTC

Conversa de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 de mai. de 2026, 18:10 UTC

Conversa de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 de mai. de 2026, 17:55 UTC

Ganhos

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 de mai. de 2026, 17:55 UTC

Conversa de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 de mai. de 2026, 17:00 UTC

Ganhos

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

29 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

29 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

29 de mai. de 2026, 16:02 UTC

Conversa de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

28.94% parte superior

Previsão para 12 meses

Média 85.8 USD 28.94%

Máximo 96 USD

Mínimo 70 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

124 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.